180.9 USD
+3.97 (+2.24%)
180.9 USD
0 (0%)
JAZZ gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. There are concerns on the financial health of JAZZ while its profitability can be described as average. JAZZ has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
JAZZ had positive earnings in the past year.
In the past year JAZZ had a positive cash flow from operations.
In multiple years JAZZ reported negative net income over the last 5 years.
In the past 5 years JAZZ always reported a positive cash flow from operatings.
1.2 Ratios
JAZZ has a Return On Assets of -3.24%. This is in the better half of the industry: JAZZ outperforms 73.96% of its industry peers.
JAZZ has a better Return On Equity (-9.31%) than 74.48% of its industry peers.
JAZZ has a better Return On Invested Capital (3.95%) than 82.29% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for JAZZ is significantly below the industry average of 12.71%.
The 3 year average ROIC (3.85%) for JAZZ is below the current ROIC(3.95%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.24% | ||
| ROE | -9.31% | ||
| ROIC | 3.95% |
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
1.3 Margins
JAZZ's Profit Margin has declined in the last couple of years.
The Operating Margin of JAZZ (10.92%) is better than 82.81% of its industry peers.
In the last couple of years the Operating Margin of JAZZ has declined.
JAZZ has a Gross Margin of 88.49%. This is amongst the best in the industry. JAZZ outperforms 90.63% of its industry peers.
In the last couple of years the Gross Margin of JAZZ has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.92% | ||
| PM (TTM) | N/A | ||
| GM | 88.49% |
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
2. Health
2.1 Basic Checks
JAZZ has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, JAZZ has less shares outstanding
JAZZ has more shares outstanding than it did 5 years ago.
The debt/assets ratio for JAZZ is higher compared to a year ago.
2.2 Solvency
JAZZ has an Altman-Z score of 1.58. This is a bad value and indicates that JAZZ is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 1.58, JAZZ perfoms like the industry average, outperforming 59.90% of the companies in the same industry.
The Debt to FCF ratio of JAZZ is 4.33, which is a neutral value as it means it would take JAZZ, 4.33 years of fcf income to pay off all of its debts.
JAZZ has a Debt to FCF ratio of 4.33. This is amongst the best in the industry. JAZZ outperforms 82.81% of its industry peers.
JAZZ has a Debt/Equity ratio of 1.09. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.09, JAZZ is not doing good in the industry: 72.40% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.09 | ||
| Debt/FCF | 4.33 | ||
| Altman-Z | 1.58 |
ROIC/WACC0.55
WACC7.15%
2.3 Liquidity
JAZZ has a Current Ratio of 1.65. This is a normal value and indicates that JAZZ is financially healthy and should not expect problems in meeting its short term obligations.
JAZZ's Current ratio of 1.65 is on the low side compared to the rest of the industry. JAZZ is outperformed by 67.71% of its industry peers.
JAZZ has a Quick Ratio of 1.44. This is a normal value and indicates that JAZZ is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of JAZZ (1.44) is worse than 63.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.65 | ||
| Quick Ratio | 1.44 |
3. Growth
3.1 Past
The earnings per share for JAZZ have decreased strongly by -58.39% in the last year.
Measured over the past 5 years, JAZZ shows a small growth in Earnings Per Share. The EPS has been growing by 5.47% on average per year.
The Revenue has been growing slightly by 4.14% in the past year.
The Revenue has been growing by 13.48% on average over the past years. This is quite good.
EPS 1Y (TTM)-58.39%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%23%
Revenue 1Y (TTM)4.14%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%6.74%
3.2 Future
JAZZ is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.82% yearly.
The Revenue is expected to grow by 7.13% on average over the next years.
EPS Next Y-74.64%
EPS Next 2Y3.08%
EPS Next 3Y5.52%
EPS Next 5Y7.82%
Revenue Next Year4.41%
Revenue Next 2Y5.24%
Revenue Next 3Y5.81%
Revenue Next 5Y7.13%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 22.17, the valuation of JAZZ can be described as rather expensive.
Based on the Price/Earnings ratio, JAZZ is valued a bit cheaper than the industry average as 79.17% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of JAZZ to the average of the S&P500 Index (25.47), we can say JAZZ is valued inline with the index average.
A Price/Forward Earnings ratio of 8.03 indicates a reasonable valuation of JAZZ.
JAZZ's Price/Forward Earnings ratio is rather cheap when compared to the industry. JAZZ is cheaper than 90.63% of the companies in the same industry.
JAZZ's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 34.42.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.17 | ||
| Fwd PE | 8.03 |
4.2 Price Multiples
JAZZ's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. JAZZ is cheaper than 83.85% of the companies in the same industry.
JAZZ's Price/Free Cash Flow ratio is rather cheap when compared to the industry. JAZZ is cheaper than 90.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.87 | ||
| EV/EBITDA | 11.71 |
4.3 Compensation for Growth
The decent profitability rating of JAZZ may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)4.06
EPS Next 2Y3.08%
EPS Next 3Y5.52%
5. Dividend
5.1 Amount
JAZZ does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
180.9
+3.97 (+2.24%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners106.51%
Inst Owner Change-3.3%
Ins Owners2.49%
Ins Owner Change-0.76%
Market Cap10.99B
Revenue(TTM)4.16B
Net Income(TTM)-368.48M
Analysts84.8
Price Target193.81 (7.14%)
Short Float %8.7%
Short Ratio6.03
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.15%
Min EPS beat(2)-6.35%
Max EPS beat(2)34.65%
EPS beat(4)2
Avg EPS beat(4)-6.25%
Min EPS beat(4)-64.64%
Max EPS beat(4)34.65%
EPS beat(8)4
Avg EPS beat(8)-5.06%
EPS beat(12)4
Avg EPS beat(12)-14.55%
EPS beat(16)7
Avg EPS beat(16)-9.8%
Revenue beat(2)0
Avg Revenue beat(2)-1.26%
Min Revenue beat(2)-2.09%
Max Revenue beat(2)-0.43%
Revenue beat(4)1
Avg Revenue beat(4)-3.13%
Min Revenue beat(4)-10.66%
Max Revenue beat(4)0.66%
Revenue beat(8)1
Avg Revenue beat(8)-2.61%
Revenue beat(12)1
Avg Revenue beat(12)-2.27%
Revenue beat(16)3
Avg Revenue beat(16)-2.04%
PT rev (1m)1.64%
PT rev (3m)2.12%
EPS NQ rev (1m)11.04%
EPS NQ rev (3m)12.1%
EPS NY rev (1m)-0.91%
EPS NY rev (3m)10.64%
Revenue NQ rev (1m)-0.93%
Revenue NQ rev (3m)-0.68%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)-0.28%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.17 | ||
| Fwd PE | 8.03 | ||
| P/S | 2.64 | ||
| P/FCF | 8.87 | ||
| P/OCF | 7.9 | ||
| P/B | 2.78 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.71 |
EPS(TTM)8.16
EY4.51%
EPS(NY)22.52
Fwd EY12.45%
FCF(TTM)20.39
FCFY11.27%
OCF(TTM)22.9
OCFY12.66%
SpS68.42
BVpS65.15
TBVpS-40.06
PEG (NY)N/A
PEG (5Y)4.06
Graham Number109.37
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.24% | ||
| ROE | -9.31% | ||
| ROCE | 5% | ||
| ROIC | 3.95% | ||
| ROICexc | 5.1% | ||
| ROICexgc | 55.75% | ||
| OM | 10.92% | ||
| PM (TTM) | N/A | ||
| GM | 88.49% | ||
| FCFM | 29.8% |
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
ROICexc(3y)4.89%
ROICexc(5y)5.68%
ROICexgc(3y)31.42%
ROICexgc(5y)35.77%
ROCE(3y)4.87%
ROCE(5y)5.36%
ROICexgc growth 3Y32.25%
ROICexgc growth 5Y-7.79%
ROICexc growth 3Y35.45%
ROICexc growth 5Y-6.86%
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
F-Score5
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.09 | ||
| Debt/FCF | 4.33 | ||
| Debt/EBITDA | 3.8 | ||
| Cap/Depr | 22.29% | ||
| Cap/Sales | 3.68% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 122.16% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.65 | ||
| Quick Ratio | 1.44 | ||
| Altman-Z | 1.58 |
F-Score5
WACC7.15%
ROIC/WACC0.55
Cap/Depr(3y)31.05%
Cap/Depr(5y)47.54%
Cap/Sales(3y)5.31%
Cap/Sales(5y)6.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-58.39%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%23%
EPS Next Y-74.64%
EPS Next 2Y3.08%
EPS Next 3Y5.52%
EPS Next 5Y7.82%
Revenue 1Y (TTM)4.14%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%6.74%
Revenue Next Year4.41%
Revenue Next 2Y5.24%
Revenue Next 3Y5.81%
Revenue Next 5Y7.13%
EBIT growth 1Y-35.5%
EBIT growth 3Y22.09%
EBIT growth 5Y6.42%
EBIT Next Year-54.85%
EBIT Next 3Y4.81%
EBIT Next 5Y9.15%
FCF growth 1Y42.84%
FCF growth 3Y22.51%
FCF growth 5Y17.8%
OCF growth 1Y9.88%
OCF growth 3Y21.49%
OCF growth 5Y12.45%
JAZZ PHARMACEUTICALS PLC / JAZZ FAQ
Can you provide the ChartMill fundamental rating for JAZZ PHARMACEUTICALS PLC?
ChartMill assigns a fundamental rating of 4 / 10 to JAZZ.
What is the valuation status of JAZZ PHARMACEUTICALS PLC (JAZZ) stock?
ChartMill assigns a valuation rating of 6 / 10 to JAZZ PHARMACEUTICALS PLC (JAZZ). This can be considered as Fairly Valued.
Can you provide the profitability details for JAZZ PHARMACEUTICALS PLC?
JAZZ PHARMACEUTICALS PLC (JAZZ) has a profitability rating of 6 / 10.
How financially healthy is JAZZ PHARMACEUTICALS PLC?
The financial health rating of JAZZ PHARMACEUTICALS PLC (JAZZ) is 3 / 10.
Can you provide the expected EPS growth for JAZZ stock?
The Earnings per Share (EPS) of JAZZ PHARMACEUTICALS PLC (JAZZ) is expected to decline by -74.64% in the next year.